Advertisement
"As a company focused on the biosecurity of the country, we are honored to be presenting at this vital conference," said PharmAthene President and Chief Executive Officer, David P. Wright. "The PHEMCE conference comes at a critical time in our Nation's history as we collectively wrestle with the many challenges of providing adequate stockpiles of modern vaccines ready for a host of potential emergencies."
Advertisement
The HHS Public Health Emergency Medical Countermeasures Enterprise (PHEMCE) Stakeholders Workshop 2009 and BARDA Industry Day will bring together public and private sector stakeholders for a dynamic dialogue on the current state of medical countermeasure preparedness, PHEMCE initiatives in the past year, and plans for moving forward to enhance national capabilities to respond to a public health emergency.
"This HHS sponsored workshop is shedding much needed light on a dangerously neglected area," commented former Secretary of Health and Human Services, Tommy Thompson. "As we have learned with the H1N1 virus, it's imperative to have adequate stockpiles of proven vaccine ready for an emergency. The HHS PHEMCE workshop is very timely given the WMD Commission's conclusion that terrorists are much more likely to attack America with a biological weapon than a nuclear weapon. Now that our national experts have made this warning clear, we need to take the immediate steps necessary to protect against potential biological attacks against the U.S. homeland. In particular, we need to move forward efforts to build and stockpile appropriate biological countermeasures, such as next-generation anthrax vaccines, recombinant influenza vaccines, and novel antivirals."
About PharmAthene, Inc.
PharmAthene was formed to meet the critical needs of the United States and its allies by developing and commercializing medical countermeasures against biological and chemical weapons. PharmAthene's lead product development programs include:
For more information about PharmAthene, please visit www.PharmAthene.com .
Statement on Cautionary Factors
Except for the historical information presented herein, matters discussed may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Statements that are not historical facts, including statements proceeded by, followed by, or that include the words "potential"; "believe"; "anticipate"; "intend"; "plan"; "expect"; "estimate"; "could"; "may"; "should"; or similar statements are forward-looking statements. PharmAthene disclaims, however, any intent or obligation to update these forward-looking statements. Risks and uncertainties include risk associated with the reliability of the results of the studies relating to human safety and possible adverse effects resulting from the administration of the Company's product candidates, unexpected funding delays and/or reductions or elimination of U.S. government funding for one or more of the Company's development programs, including without limitation our bid related to SparVax(TM) under the DHHS Request for Proposals for an Anthrax Recombinant Protective Antigen (rPA) Vaccine for the Strategic National Stockpile, the award of government contracts to our competitors, unforeseen safety issues, challenges related to the development, scale-up, technology transfer, and/or process validation of manufacturing processes for our product candidates, unexpected determinations that these product candidates prove not to be effective and/or capable of being marketed as products, as well as risks detailed from time to time in PharmAthene's Forms 10-K and 10-Q under the caption "Risk Factors" and in its other reports filed with the U.S. Securities and Exchange Commission (the "SEC").
Copies of PharmAthene's public disclosure filings are available from its investor relations department and our website under the investor relations tab at www.PharmAthene.com.
-- SparVax(TM) - a second generation recombinant protective antigen (rPA) anthrax vaccine -- Third generation rPA anthrax vaccine -- Valortim® - a fully human monoclonal antibody for the prevention and treatment of anthrax infection -- Protexia® - a novel bioscavenger for the prevention and treatment of morbidity and mortality associated with exposure to chemical nerve agents -- RypVax(TM) - a recombinant dual antigen vaccine for plague
SOURCE PharmAthene, Inc.
